GH Guardant Health Inc

Price (delayed)

$41.89

Market cap

$4.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.12

Enterprise value

$5.06B

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health ...

Highlights
The gross profit has grown by 34% YoY and by 6% from the previous quarter
Guardant Health's revenue has increased by 31% YoY and by 4.7% from the previous quarter
Guardant Health's quick ratio has plunged by 78% YoY and by 14% from the previous quarter
GH's equity is down by 37% YoY and by 17% QoQ

Key stats

What are the main financial stats of GH
Market
Shares outstanding
101.92M
Market cap
$4.27B
Enterprise value
$5.06B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.01
Price to sales (P/S)
10.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.93
Earnings
Revenue
$391.09M
EBIT
-$416.5M
EBITDA
-$364.36M
Free cash flow
-$309.49M
Per share
EPS
-$4.12
Free cash flow per share
-$3.04
Book value per share
$5.23
Revenue per share
$3.84
TBVPS
$20.74
Balance sheet
Total assets
$2.13B
Total liabilities
$1.6B
Debt
$1.36B
Equity
$533.04M
Working capital
$884.47M
Liquidity
Debt to equity
2.55
Current ratio
4.87
Quick ratio
4.57
Net debt/EBITDA
-2.16
Margins
EBITDA margin
-93.2%
Gross margin
67.7%
Net margin
-107.2%
Operating margin
-109%
Efficiency
Return on assets
-18.9%
Return on equity
-62.7%
Return on invested capital
-15.5%
Return on capital employed
-21.9%
Return on sales
-106.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GH stock price

How has the Guardant Health stock price performed over time
Intraday
-0.88%
1 week
2.5%
1 month
-2.58%
1 year
-67.22%
YTD
-58.12%
QTD
-36.76%

Financial performance

How have Guardant Health's revenue and profit performed over time
Revenue
$391.09M
Gross profit
$264.94M
Operating income
-$426.48M
Net income
-$419.24M
Gross margin
67.7%
Net margin
-107.2%
The gross profit has grown by 34% YoY and by 6% from the previous quarter
Guardant Health's revenue has increased by 31% YoY and by 4.7% from the previous quarter
GH's operating income is down by 30% YoY and by 3.8% from the previous quarter
Guardant Health's net income has decreased by 25% YoY and by 3.3% QoQ

Growth

What is Guardant Health's growth rate over time

Valuation

What is Guardant Health stock price valuation
P/E
N/A
P/B
8.01
P/S
10.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.93
The EPS has declined by 22% year-on-year and by 3% since the previous quarter
The P/B is 48% less than the last 4 quarters average of 15.6
GH's equity is down by 37% YoY and by 17% QoQ
The P/S is 63% below the last 4 quarters average of 30.0
Guardant Health's revenue has increased by 31% YoY and by 4.7% from the previous quarter

Efficiency

How efficient is Guardant Health business performance
The ROE has plunged by 103% YoY and by 15% from the previous quarter
Guardant Health's ROIC has increased by 17% YoY but it has decreased by 3.3% from the previous quarter
GH's ROA is down by 6% since the previous quarter
The return on sales is up by 3.8% year-on-year

Dividends

What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GH.

Financial health

How did Guardant Health financials performed over time
Guardant Health's total assets is 33% more than its total liabilities
Guardant Health's quick ratio has plunged by 78% YoY and by 14% from the previous quarter
GH's current ratio has dropped by 77% year-on-year and by 15% since the previous quarter
The debt is 155% greater than the equity
GH's debt to equity has surged by 60% year-on-year and by 21% since the previous quarter
GH's equity is down by 37% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.